GRIFOLS SHARED SERVICES NORTH AMERICA, INC. for GRIFOLS SHARED SERVICES NORTH AMERICA INC
What was lobbied
2 issue areas, each in the filer's own words, with who lobbied on it and where.
Health Issues HCR
H.R. 1476 / S. 694 Preserving Life-Saving Access to Specialty Medicines in America Act (PLASMA Act);Phases in manufacturer discounts for plasma‑derived therapies under the Medicare Part D Manufacturer Discount Program, gradually increasing required discounts over several years to avoid sudden cost impacts on access to plasma‑derived medicines. H.R. 1143 Medicare IVIG Access Enhancement Act of 2025;Expands Medicare coverage for in‑home administration of intravenous immune globulin (IVIG) to include treatment of chronic inflammatory demyelinating polyneuropathy (CIDP) and multifocal motor neuropathy, in addition to primary immune deficiency diseases. H.R.8528 - PI Post Acute Access Act: This bill allows for separate payment under Medicare to skilled nursing facilities for items and services that are needed to administer intravenous immune globin (IVIG) to patients with primary immune deficiency diseases (rare genetic disorders that impair the immune system and increase vulnerability for other infections). H.R. 2343 John W. Walsh Alpha‑1 Home Infusion Act of 2025;Provides Medicare coverage for at‑home augmentation therapy for beneficiaries with emphysema resulting from severe hereditary alpha‑1 antitrypsin (AAT) deficiency when furnished by qualified home infusion therapy suppliers. Issues related to Most Favored Nations drug pricing proposals (incl. H.R. 7837) Most Favored Patient Act of 2026; Directs the Center for Medicare and Medicaid Innovation to test a model implementing most‑favored‑nation drug pricing, tying Medicare payment rates to lower prices paid in comparable foreign countries. Issues related to the implementation of P.L. 117-169, the Inflation Reduction Act; drug price negotiations, Part D rebate Issues related to the 340B program
Foreign entity interest: Issues related to the delivery of plasma-derived therapies.
| Lobbyist | Covered position, as disclosed |
|---|---|
| ROSEMARY GARZA | — |
| CHRISTOPHER HEALEY | — |
| KATHERINE PAJEWSKI | — |
| MICHAEL PIERSALL | — |
Tariff (miscellaneous tariff bills) TAR
Issues related to tariff policy; tariffs on pharmaceuticals and related products
Foreign entity interest: Issues related to the delivery of plasma-derived therapies
| Lobbyist | Covered position, as disclosed |
|---|---|
| ROSEMARY GARZA | — |
| CHRISTOPHER HEALEY | — |
| KATHERINE PAJEWSKI | — |
| MICHAEL PIERSALL | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.